Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BTF3-siRNA
- Development stage
- Preclinical
- Lead developer
- The First Hospital of Jilin University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
BTF3-siRNA is a small interfering RNA (siRNA) designed to silence the expression of Basic Transcription Factor 3 (BTF3). BTF3 is a component of the nascent polypeptide-associated complex (NAC) and acts as an RNA polymerase II transcription factor. In preclinical studies, particularly in malignant melanoma, silencing BTF3 using siRNA has been shown to inhibit cell proliferation, induce cell cycle arrest in the G1 and S phases, and promote apoptosis. Research conducted at The First Hospital of Jilin University indicates that BTF3 is overexpressed in various tumors and its knockdown reduces tumorigenicity in vivo.
- Other names
- basic transcription factor 3 siRNAsi-BTF3si-BTF-3si-BTF 3
02
Targets
Innate immune RNA sensorsBTF3 (Basic transcription factor 3)
Beyond the preview
Go deeper on BTF3-siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BTF3-siRNA.